HomeCompareSACC vs JNJ

SACC vs JNJ: Dividend Comparison 2026

SACC yields 3.46% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SACC wins by $252.00 in total portfolio value
10 years
SACC
SACC
● Live price
3.46%
Share price
$24.98
Annual div
$0.86
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.3K
Annual income
$0.35
Full SACC calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — SACC vs JNJ

📍 SACC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSACCJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SACC + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SACC pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SACC
Annual income on $10K today (after 15% tax)
$294.05/yr
After 10yr DRIP, annual income (after tax)
$0.30/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $703.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SACC + JNJ for your $10,000?

SACC: 50%JNJ: 50%
100% JNJ50/50100% SACC
Portfolio after 10yr
$20.1K
Annual income
$414.06/yr
Blended yield
2.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SACC
No analyst data
Altman Z
0.3
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SACC buys
0
JNJ buys
0
No recent congressional trades found for SACC or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSACCJNJ
Forward yield3.46%3.36%
Annual dividend / share$0.86$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR-50%5.8%
Portfolio after 10y$20.3K$20.0K
Annual income after 10y$0.35$827.78
Total dividends collected$349.00$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SACC vs JNJ ($10,000, DRIP)

YearSACC PortfolioSACC Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,873$172.97$10,676$355.77+$197.00SACC
2$11,722$87.88$11,407$389.39+$315.00SACC
3$12,587$44.27$12,198$426.53+$389.00SACC
4$13,490$22.21$13,056$467.62+$434.00SACC
5$14,445$11.13$13,987$513.12+$458.00SACC
6$15,462$5.57$14,998$563.56+$464.00SACC
7$16,547$2.78$16,098$619.52+$449.00SACC
8$17,707$1.39$17,295$681.69+$412.00SACC
9$18,947$0.70$18,599$750.82+$348.00SACC
10$20,274$0.35$20,022$827.78+$252.00SACC

SACC vs JNJ: Complete Analysis 2026

SACCStock

Sachem Capital Corp. is a real estate finance company, which engages in the provision of real estate investment trust services. The firm specializes in originating, underwriting, funding, servicing, and managing services for a portfolio of short-term loans. It offers short-term, secured, and non-banking loans to real estate investors to fund their acquisition, renovation, rehabilitation, or development of residential and commercial properties. The company was founded by Jeffrey C. Villano and John L. Villano in January 2016 and is headquartered in Branford, CT.

Full SACC Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this SACC vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SACC vs SCHDSACC vs JEPISACC vs OSACC vs KOSACC vs MAINSACC vs ABBVSACC vs MRKSACC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.